Saturday, August 9, 2025
Science
No Result
View All Result
  • Login
  • HOME
  • SCIENCE NEWS
  • CONTACT US
  • HOME
  • SCIENCE NEWS
  • CONTACT US
No Result
View All Result
Scienmag
No Result
View All Result
Home Science News Biology

Advances in priming B cell immunity against HIV pave the way to future HIV vaccines, shows quartet of new studies

May 16, 2024
in Biology
Reading Time: 5 mins read
0
Advances in priming B cell immunity against HIV pave the way to future HIV vaccines, shows quartet of new studies
66
SHARES
596
VIEWS
Share on FacebookShare on Twitter
ADVERTISEMENT
ADVERTISEMENT

Scientists have made several advances in the design of a class of HIV vaccines that could offer broad protection against the virus, according to four new research papers published this week in Science, Science Translational Medicine, and Science Immunology. “The studies […] exemplify progress in the rational design of [germline-targeting] HIV-1 vaccines, and what is being learned will guide [germline-targeting] programs for inducing [broadly neutralizing antibodies] against other human pathogens,” Rogier Sanders and John Moore write in a related Perspective on the new articles. As the HIV epidemic enters its fifth decade, scientists have poured time and resources into developing vaccine candidates for the virus. However, health authorities still lack a working, approved vaccine that induces broadly neutralizing antibodies, which can neutralize the most common circulating strains of HIV. One solution involves a process called germline targeting, where scientists use a series of proteins targeted by the immune system (immunogens) to shepherd and “prime” young B cells as they mature in sites called germinal centers, with the goal of coaxing the cells to produce broadly neutralizing antibodies against HIV. In the first paper in Science, Jon Steichen and colleagues tested the protective effects of a new germline-targeting strategy based on the N332-GT5 trimer, a component of the HIV viral envelope. Leveraging cryo-electron microscopy, the team showed that their approach successfully primed and boosted quantities of B cells that secret precursors to BG18 – an anti-HIV broadly neutralizing antibody – in a group of eight rhesus macaques. Taking a different delivery approach in the second Science study, Zhenfei Xie and colleagues demonstrated they could prime B cells with N332-GT5 via mRNA, which they delivered via lipid nanoparticles. When given to humanized mice, the mRNA delivered both the primary immunogen (N332-GT5) and two additional immunogens that further primed the target B cells. Together, these immunogens kickstarted the activation and expansion of B cells that secreted precursors to BG18, with Xie et al. hypothesizing that their strategy could reduce undesirable off-target binding. Meanwhile, in a study in Science Translational Medicine, Christopher Cottrell and colleagues designed a new nanoparticle immunogen as a boost to germline-targeting HIV vaccines. They first primed mice with an immunogen named eOD-Gt8 60mer, which was previously found to induce precursors to anti-HIV, VRC01-class broadly neutralizing antibodies in a phase 1 trial. After priming, Cottrell et al. then vaccinated mice with another immunogen named core-g28v2 60mer (in both protein and mRNA form) as a “first boost.” They found that this prime-boost approach elicited VRC01-class antibodies that were precursors to broadly neutralizing antibodies and neutralized HIV-like pseudoviruses in culture. Finally, in a study in Science Immunology, Xuesong Wang and colleagues showed that they could deliver eOD-Gt8 60mer as an initial priming immunogen via mRNA encapsulated in lipid nanoparticles. The researchers transferred several different humanized B cell lines into mice to mimic the competition between B cells that occurs during immunization. Their priming strategy coaxed B cells to diversify, participate in germinal centers, and acquire mutations and characteristics needed to secrete VRC01-class antibodies. In their related Perspective, Sanders and Moore add that the results provide a strong proof-of-concept for promising germline-targeting approaches, noting that the N332-GT5 trimer is now in a phase 1 trial.

Scientists have made several advances in the design of a class of HIV vaccines that could offer broad protection against the virus, according to four new research papers published this week in Science, Science Translational Medicine, and Science Immunology. “The studies […] exemplify progress in the rational design of [germline-targeting] HIV-1 vaccines, and what is being learned will guide [germline-targeting] programs for inducing [broadly neutralizing antibodies] against other human pathogens,” Rogier Sanders and John Moore write in a related Perspective on the new articles. As the HIV epidemic enters its fifth decade, scientists have poured time and resources into developing vaccine candidates for the virus. However, health authorities still lack a working, approved vaccine that induces broadly neutralizing antibodies, which can neutralize the most common circulating strains of HIV. One solution involves a process called germline targeting, where scientists use a series of proteins targeted by the immune system (immunogens) to shepherd and “prime” young B cells as they mature in sites called germinal centers, with the goal of coaxing the cells to produce broadly neutralizing antibodies against HIV. In the first paper in Science, Jon Steichen and colleagues tested the protective effects of a new germline-targeting strategy based on the N332-GT5 trimer, a component of the HIV viral envelope. Leveraging cryo-electron microscopy, the team showed that their approach successfully primed and boosted quantities of B cells that secret precursors to BG18 – an anti-HIV broadly neutralizing antibody – in a group of eight rhesus macaques. Taking a different delivery approach in the second Science study, Zhenfei Xie and colleagues demonstrated they could prime B cells with N332-GT5 via mRNA, which they delivered via lipid nanoparticles. When given to humanized mice, the mRNA delivered both the primary immunogen (N332-GT5) and two additional immunogens that further primed the target B cells. Together, these immunogens kickstarted the activation and expansion of B cells that secreted precursors to BG18, with Xie et al. hypothesizing that their strategy could reduce undesirable off-target binding. Meanwhile, in a study in Science Translational Medicine, Christopher Cottrell and colleagues designed a new nanoparticle immunogen as a boost to germline-targeting HIV vaccines. They first primed mice with an immunogen named eOD-Gt8 60mer, which was previously found to induce precursors to anti-HIV, VRC01-class broadly neutralizing antibodies in a phase 1 trial. After priming, Cottrell et al. then vaccinated mice with another immunogen named core-g28v2 60mer (in both protein and mRNA form) as a “first boost.” They found that this prime-boost approach elicited VRC01-class antibodies that were precursors to broadly neutralizing antibodies and neutralized HIV-like pseudoviruses in culture. Finally, in a study in Science Immunology, Xuesong Wang and colleagues showed that they could deliver eOD-Gt8 60mer as an initial priming immunogen via mRNA encapsulated in lipid nanoparticles. The researchers transferred several different humanized B cell lines into mice to mimic the competition between B cells that occurs during immunization. Their priming strategy coaxed B cells to diversify, participate in germinal centers, and acquire mutations and characteristics needed to secrete VRC01-class antibodies. In their related Perspective, Sanders and Moore add that the results provide a strong proof-of-concept for promising germline-targeting approaches, noting that the N332-GT5 trimer is now in a phase 1 trial.



Journal

Science

DOI

10.1126/science.adj8321

Article Title

Vaccine priming of rare HIV broadly neutralizing antibody precursors in nonhuman primates

Article Publication Date

17-May-2024

Share26Tweet17
Previous Post

NRG Oncology announces new leadership of three committees

Next Post

The vicious cycle of protein clumping in Alzheimer’s disease and normal aging

Related Posts

blank
Biology

Scientists Discover Novel Mechanism Behind Cellular Tolerance to Anticancer Drugs

August 9, 2025
blank
Biology

Onchocerca ochengi Infection Impacts Gerbil Behavior, Physiology

August 9, 2025
blank
Biology

Decoding Finch Louse Fly Morphotypes: Taxonomy Insight

August 9, 2025
blank
Biology

How Immune Cells Flip the Switch to Launch an Attack

August 9, 2025
blank
Biology

Molecular Study and Risks of Hepatozoon Canis in Haryana Dogs

August 8, 2025
blank
Biology

Unraveling the Nuclear Phosphoinositide-p53 Signalosome: A Key Regulator of Cell Motility

August 8, 2025
Next Post
The vicious cycle of protein clumping in Alzheimer’s disease and normal aging

The vicious cycle of protein clumping in Alzheimer’s disease and normal aging

  • Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    27531 shares
    Share 11009 Tweet 6881
  • University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept

    943 shares
    Share 377 Tweet 236
  • Bee body mass, pathogens and local climate influence heat tolerance

    641 shares
    Share 256 Tweet 160
  • Researchers record first-ever images and data of a shark experiencing a boat strike

    507 shares
    Share 203 Tweet 127
  • Warm seawater speeding up melting of ‘Doomsday Glacier,’ scientists warn

    310 shares
    Share 124 Tweet 78
Science

Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!

RECENT NEWS

  • Cholesterol Balance Drives Recovery After Revascularization
  • Circulating Hsp70 Signals Early Thoracic Cancer Spread
  • Integrating Rural Culture and Ecology: China’s Innovation
  • Evolving Plasmodium falciparum Drug Resistance in Uganda

Categories

  • Agriculture
  • Anthropology
  • Archaeology
  • Athmospheric
  • Biology
  • Bussines
  • Cancer
  • Chemistry
  • Climate
  • Earth Science
  • Marine
  • Mathematics
  • Medicine
  • Pediatry
  • Policy
  • Psychology & Psychiatry
  • Science Education
  • Social Science
  • Space
  • Technology and Engineering

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 4,860 other subscribers

© 2025 Scienmag - Science Magazine

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • HOME
  • SCIENCE NEWS
  • CONTACT US

© 2025 Scienmag - Science Magazine

Discover more from Science

Subscribe now to keep reading and get access to the full archive.

Continue reading